Donate
PATH Program

Center for Vaccine Innovation and Access

Everyone has a right to lifesaving vaccines, no matter where they live. The Center for Vaccine Innovation and Access (CVIA) accelerates the development and delivery of lifesaving vaccines for the communities facing the greatest health risks around the world.

Read more
CVIA in numbers
100s
of millions of people immunized
24+
vaccines licensed
30
years accelerating vaccine access

Saving lives with vaccines

CVIA has played a critical role in some of immunization’s greatest successes of the past 30 years: The world’s first malaria vaccine, which has reached more than 2 million children (and counting); elimination of meningitis A epidemics in Africa where MenAfriVac® vaccine has been introduced, with more than 360 million people immunized; protecting more than 300 million children from Japanese encephalitis, a potentially debilitating and fatal brain infection; vaccinating millions of girls in 30 countries against human papillomavirus (HPV), the leading cause of cervical cancer; and introducing the first typhoid conjugate vaccine in six countries, protecting more than 56 million children.

Tackling the toughest diseases

Our portfolio of vaccines in development and deployment includes those against the most dangerous childhood illnesses, such as pneumonia, diarrhea, and malaria. For example, beginning in 2011, we partnered to develop the world’s first malaria vaccine, and we supported implementation of the pivotal pilot introduction of the vaccine in Ghana, Kenya, and Malawi. PATH’s breadth of experience in malaria prevention and treatment, paired with our expertise in malaria vaccine implementation, uniquely equips us to support countries as they plan their rollouts of malaria vaccines.

Focus areas
Rapidly responding to outbreaks

We mobilized quickly to respond to the COVID-19 pandemic, including supporting country vaccine readiness, COVAX, and other efforts to ensure equitable access to vaccines; vaccine development and manufacturing scale-up; and vaccine clinical evaluation efforts.

Pioneering new vaccines

We supported the development and introduction of MenAfriVac®, a conjugate meningitis A vaccine that has been delivered to more than 360 million people across the African meningitis belt and virtually eliminated meningitis A wherever it has been used. PATH also partnered on MenFive®—the first vaccine to protect against meningitis A, C, W, Y, and X and with the potential to stop meningococcal meningitis epidemics in the meningitis belt in Africa, once and for all.

Expanding access for global impact

We transformed a Japanese encephalitis vaccine that had been available only in China into an internationally approved tool that has been delivered to more than 300 million people. With partners, we contributed to making a more affordable pneumococcal conjugate vaccine, PNEUMOSIL®, increasing protection for children against deadly pneumonia and other pneumococcal diseases like meningitis, sepsis, and otitis media.

Advancing immunization equity

We supported country-led efforts to assess the typhoid disease burden, secure support for typhoid vaccine introduction from Gavi, the Vaccine Alliance, and leveraged typhoid vaccine introduction to reach children with other essential vaccines. In Malawi, PATH partnered with the immunization and education ministries to deliver typhoid, polio, and measles vaccines in an integrated campaign.

Improving vaccine supply and affordability

We partnered with manufacturers to ensure robust supplies and cost competition of lifesaving vaccines that can be used by the World Health Organization and Gavi—and, therefore, made widely available to communities across the world. Our support on clinical development, quality systems, and regulatory strategies has resulted in more than a dozen vaccines approved (prequalified) by the World Health Organization.

Latest news

Get our updates

  1. Moving the Needle e-newsletter

    Moving the Needle provides updates from CVIA on our vaccine development efforts, as well as related supporting work, such as developing human challenge models, building capacity of developing-country vaccine manufacturers, and evaluating new adjuvants and other novel vaccine technologies.

  2. Immunization Matters e-newsletter

    Immunization Matters provides updates from CVIA on late-stage and licensed vaccines included in our portfolio as well as our work on health economics and optimization, operations research, and support to countries.

  3. DefeatDD website

    PATH's Defeat Diarrheal Disease Initiative was started to raise awareness of the burden of diarrheal disease and help increase access to the solutions. We need your help to make a stink about the problem, and our website gives you the tools to do just that.

  4. PATH's malaria vaccine website

    PATH's malaria vaccine work drives transformative innovation to save lives and improve health, especially among women and children. We work with partners in private industry, government, and academia to develop malaria vaccines.

  5. Take on Typhoid website

    The Coalition against Typhoid (CaT) and the Typhoid Vaccine Acceleration Consortium (TyVAC) have joined forces to Take on Typhoid. Together, we are working to focus attention on typhoid and the need for typhoid conjugate vaccines and water, sanitation, and hygiene interventions to reduce the burden and impact of typhoid fever.

  6. HPVflash e-newsletter

    In HPVflash, PATH provides updates on progress in the field, new literature, events, and partnerships in an effort to eliminate cervical cancer.

More about CVIA

Meet the team

  1. Dr. Melanie Saville

    Chief Scientific Officer, PATH

  2. Jessica Milman

    Global Head, Center for Vaccine Innovation and Access (CVIA)

  3. Margaret Toher

    Global Head, Regulatory, Center for Vaccine Innovation and Access (CVIA)

  4. Deborah Atherly

    Global Head of Policy, Access, and Introduction, Center for Vaccine Innovation and Access

  5. Dwayne Wilson

    Global Head, Quality, Center for Vaccine Innovation and Access (CVIA)

  6. Kerim Chitour, MD

    Global Head of Clinical, Center for Vaccine Innovation and Access

  7. Simone Blayer

    Global Head, Development (Chemistry, Manufacturing, and Controls), CVIA

  8. Ashley Birkett

    Global Head, Bacterial and Parasitic Diseases, Center for Vaccine Innovation and Access

  9. John Konz

    Global Head, Viral Diseases, CVIA

  10. Gretchen MacLeod

    Global Head, Integrated Portfolio and Financial Management, CVIA

Our partners

Our partners

  • Bill & Melinda Gates Foundation

  • The United Kingdom’s Foreign, Commonwealth & Development Office

  • Coalition for Epidemic Preparedness Innovations

  • The US Agency for International Development

  • Gavi, the Vaccine Alliance

  • The Global Health Innovative Technology Fund

PATH strives for vaccine equity in response to COVID-19

When COVID-19 emerged, we mobilized quickly and deployed our decades of experience advancing equitable access to vaccines and immunization to support the global COVID-19 response.

Read More
Related articles

Read our latest

166 Article s
  1. Elian Korir, the first recipient of RTS,S, the world’s first malaria vaccine plays football with his friends at Kasimba Primary School in Oyugis, Homabay County. Credit: Kabir Dhanji/Kivuli Creative/Burness/PATH.
    June 27, 2025

    A shot of hope: How the malaria vaccine is helping to change lives in Kenya

    In 2019, Elian Korir made history as the first child in Kenya to receive the malaria vaccine. Now six years old, Elian is thriving—and his story reflects the hope and impact malaria vaccines are bringing to families across sub-Saharan Africa.
  2. A health worker drawing a vaccine into a syringe. Photo: PATH/Wendy Stone
    June 23, 2025

    Surprising research results drive progress in malaria prevention

    A recent clinical study tested the widely held assumption that giving a malaria vaccine with antimalarial drugs would enhance vaccine efficacy in adults. The unexpected results impact adult vaccination strategies and future research.
  3. vaccine refrigerator.png
    May 15, 2025

    Simplifying the vaccine cost equation

    PATH's recently updated suite of Vaccine Cost Calculators aims to help countries eligible for support from Gavi, the Vaccine Alliance, make the most of their resources.
  4. Photo: A health care worker delivers TCV during a campaign in Nepal. Credit: PATH/Rocky Prajapati
    April 24, 2025

    Humanly possible: The people making vaccine introductions a reality

    In the past two decades, the world has vaccinated more than 1 billion children and saved more than 17 million lives—an incredible achievement that is grounded in the work of thousands of people and partners who make vaccine delivery possible.
  5. A health care worker prepares a dose of typhoid conjugate vaccine for administration in Burkina Faso. Photo: PATH/Build Africa Communications.
    April 23, 2025

    Protecting progress: Vaccines are a down payment on a more prosperous future

    Global investments in immunization systems have saved millions of lives and generated tremendous economic returns. PATH advocates make the case for immunization in a shifting financial landscape.
  6. An atomic model of human papillomavirus L1 vaccine-like particles joined together to form a sphere. Image: Elsevier Ltd.
    April 14, 2025

    How a single HPV vaccine dose can prevent cervical cancer

    Subunit vaccines—which use a piece of the virus to generate an immune response—typically need boosters, but HPV vaccines broke the paradigm. PATH's Hope Randall explains how.
Next